English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe U.S. Food & Drug Administration has approved use of a new treatment option for patients with advanced or recurring uterine cancer. The news comes after completion of the first Phase III trial to statistically evaluate an anti-PD1 immunotherapy, called…
Tag: Uterine Cancer
Ultrasounds may not find this cancer in Black women
The study looked back at ultrasound data from 1,500 Black women who ended up undergoing hysterectomy at 10 health centers. The study found that having a thinner endometrium measured on transvaginal ultrasound did not mean that there was no cancer risk.
The Foundation for Women’s Cancer to Host Free Patient and Advocates Education Forum in San Diego
The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all gynecologic cancer (cervical, endometrial/uterine, ovarian, vaginal, and vulvar) patients, advocates, family members, and providers.
Using personalized medicine to target gynecological cancers
In this interview, Dr. Salani, who is also a professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA, talks about the latest research advances for these cancers and how women can help reduce their risk and help with the early detection of the five main types of gynecologic cancers: cervical, ovarian, uterine, vaginal and vulvar.
TWO CLINICAL TRIALS REVEAL ADDITION OF IMMUNOTHERAPY TO CHEMOTHERAPY REGIMEN INCREASES PROGRESSION-FREE SURVIVAL IN ENDOMETRIAL CANCER PATIENTS
The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer (EC).
GYNECOLOGIC CANCER PATIENTS REPORT TIME-RELATED BURDENS AND FINANCIAL TOXICITIES IMPACT QUALITY OF LIFE
Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
The Foundation for Women’s Cancer to Host Patient and Advocates Education Forum at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Tampa on March 24
The Foundation for Women’s Cancer will host a Patients and Advocates Education Forum and Luncheon on Friday, March 24, 2023 in Tampa, FL during the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Hair straightening chemicals associated with higher uterine cancer risk
Women who used chemical hair straightening products were at higher risk for uterine cancer compared to women who did not report using these products, according to a new study from the National Institutes of Health. The researchers found no associations with uterine cancer for other hair products that the women reported using, including hair dyes, bleach, highlights, or perms.
MD Anderson Research Highlights for August 24, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include confirmation of improving response rates in Phase I trials over the last 20 years, a novel targeted therapy combination and biomarkers of response for chimeric antigen receptor (CAR) T cell therapy in B-cell lymphomas, a combination therapy for patients with melanoma brain metastases, and new treatment options for metastatic sarcomas, HPV-driven cancers and uterine cancer.
Intricate Interplay
Kimberly Leslie, MD, was awarded a four-year, $1.8 million grant from the Department of Defense (DOD) to further study high-risk uterine cancer. Her research has led her to study the differences between natural progesterone and synthetic progestins – hormones often used for birth control – and the influence of progesterone on a tumor suppressor protein called p53. The hormones, drugs and proteins, she’s learned, influence each other and the body’s cells in complex ways.
Rutgers-Led Effort Is Close to Getting Uterine Cancer Covered by WTC Health Program
A proposed rule change would improve care and compensation for responders and survivors who developed uterine cancer after Ground Zero exposure
Women’s Wellness: Types of Gynecologic Cancers and their Warning Signs
September is Gynecologic Cancer Awareness Month. Rutgers Cancer institute of New Jersey Gynecologic Oncology Chief Dr. James Aikins reminds women about the types of gynecologic cancers and their warning signs
Researchers Identify Genes Behind Uterine Leiomyosarcoma Which May Be Treated Using Precision Medicine
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Cancer cases are rising in adolescents and young adults
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
What Every Woman Should Know About Preventing Gynecologic Cancers
The best defense against gynecologic cancer starts with preventative measures. When cancer is detected early, there is a better chance of having more effective treatment and better outcomes. While there is not a single screening test for all gynecologic cancers, learn about the ones that do exist.
Most Women Treated in New York City for Gynecologic Cancers Are Not at Increased Risk of Death From COVID-19
Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.